Exploration of MMP Function in Mouse Models of Angiogenesis

  • Anne Masset
  • Mehdi El Hour
  • Sarah Berndt
  • Nor Eddine Sounni
  • Agnès Noel
Chapter
First Online:

Abstract

Angiogenesis research has become one of the most important areas in the biomedical field. The fast expansion of this sphere of research requires the development of reliable and reproductive models applicable to the increasing number of knock-in or knock-out mice that are now available. Here, we discuss several commonly used ex vivo and in vivo models by illustrating how they pointed out the functions of matrix metalloproteinases (MMPs) during the complex angiogenic process associated with cancer progression and dissemination.

Keywords

Aortic Ring Angiogenic Response Genetic Ablation Angiogenic Switch Matrigel Plug Assay 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. Abate-Shen, C. (2006). A new generation of mouse models of cancer for translational research. Clinical Cancer Research, 12, 5274–5276.CrossRefPubMedGoogle Scholar
  2. Albini, A., & Sporn, M. B. (2007). The tumour microenvironment as a target for chemoprevention. Nature Reviews Cancer, 7, 139–147.CrossRefPubMedGoogle Scholar
  3. Almholt, K., Juncker-Jensen, A., Laerum, O. D., Dano, K., Johnsen, M., Lund, L. R., et al. (2008). Metastasis is strongly reduced by the matrix metalloproteinase inhibitor Galardin in the MMTV-PymT transgenic breast cancer model. Molecular Cancer Therapeutics, 7, 2758–2767.CrossRefPubMedGoogle Scholar
  4. Aplin, A. C., Fogel, E., Zorzi, P., & Nicosia, R. F. (2008). The aortic ring model of angiogenesis. Methods in Enzymology, 443, 119–136.CrossRefPubMedGoogle Scholar
  5. Aplin, A. C., Zhu, W. H., Fogel, E., & Nicosia, R. F. (2009). Vascular regression and survival are differentially regulated by MT1-MMP and TIMPs in the aortic ring model of angiogenesis. American Journal of Physiology – Cell Physiology, 297, C471–480.CrossRefPubMedGoogle Scholar
  6. Arbeit, J. M., Munger, K., Howley, P. M., & Hanahan, D. (1994). Progressive squamous epithelial neoplasia in K14-human papillomavirus type 16 transgenic mice. Journal of Virology, 68, 4358–4368.PubMedGoogle Scholar
  7. Baeriswyl, V., & Christofori, G. (2009). The angiogenic switch in carcinogenesis. Seminars in Cancer Biology, 19, 329–337.CrossRefPubMedGoogle Scholar
  8. Bergers, G., & Benjamin, L. E. (2003). Tumorigenesis and the angiogenic switch. Nature Reviews Cancer, 3, 401–410.CrossRefPubMedGoogle Scholar
  9. Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., et al. (2000). Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nature Cell Biology, 2, 737–744.CrossRefPubMedGoogle Scholar
  10. Bergers, G., Hanahan, D., & Coussens, L. M. (1998). Angiogenesis and apoptosis are cellular parameters of neoplastic progression in transgenic mouse models of tumorigenesis. International Journal of Developmental Biology, 42, 995–1002.PubMedGoogle Scholar
  11. Berndt, S., Bruyère, F., Jost, M., Edwards, D. R., & Noël, A. (2008). Chapter 16: In vitro and in vivo models of angiogenesis to dissect MMP functions. In D. R. Edwards, G. Hoyer-Hansen, F. Blasi, & B. F. Sloane (Eds), The cancer degradome: Proteases and cancer biology, Springer, NY: (pp. 303–323).Google Scholar
  12. Berndt, S., d’Hauterive, S. P., Blacher, S., Pequeux, C., Lorquet, S., Munaut, C., et al. (2006). Angiogenic activity of human chorionic gonadotropin through LH receptor activation on endothelial and epithelial cells of the endometrium. The FASEB Journal, 20, 2630–2632.CrossRefPubMedGoogle Scholar
  13. Bruyere, F., & Noel, A. (2010). Lymphangiogenesis: In vitro and in vivo models. The FASEB Journal, 24, 8–21.CrossRefPubMedGoogle Scholar
  14. Burbridge, M. F., Coge, F., Galizzi, J. P., Boutin, J. A., West, D. C., & Tucker, G. C. (2002). The role of the matrix metalloproteinases during in vitro vessel formation. Angiogenesis, 5, 215–226.CrossRefPubMedGoogle Scholar
  15. Chabottaux, V., & Noel, A. (2007). Breast cancer progression: Insights into multifaceted matrix metalloproteinases. Clinical and Experimental Metastasis, 24, 647–656.CrossRefPubMedGoogle Scholar
  16. Cheng, X. W., Kuzuya, M., Nakamura, K., Maeda, K., Tsuzuki, M., Kim, W., et al. (2007). Mechanisms underlying the impairment of ischemia-induced neovascularization in matrix metalloproteinase 2-deficient mice. Circulation Research, 100, 904–913.CrossRefPubMedGoogle Scholar
  17. Chun, T. H., Sabeh, F., Ota, I., Murphy, H., McDonagh, K. T., Holmbeck, K., et al. (2004). MT1-MMP-dependent neovessel formation within the confines of the three-dimensional extracellular matrix. Journal of Cell Biology, 167, 757–767.CrossRefPubMedGoogle Scholar
  18. Coussens, L. M., Hanahan, D., & Arbeit, J. M. (1996). Genetic predisposition and parameters of malignant progression in K14-HPV16 transgenic mice. The American Journal of Pathology, 149, 1899–1917.PubMedGoogle Scholar
  19. Coussens, L. M., Tinkle, C. L., Hanahan, D., & Werb, Z. (2000). MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell, 103, 481–490.CrossRefPubMedGoogle Scholar
  20. Egeblad, M., & Werb, Z. (2002). New functions for the matrix metalloproteinases in cancer progression. Nature Reviews Cancer, 2, 161–174.CrossRefPubMedGoogle Scholar
  21. Fanjul-Fernandez, M., Folgueras, A. R., Cabrera, S., & Lopez-Otin, C. (2009). Matrix metalloproteinases: Evolution, gene regulation and functional analysis in mouse models. Biochimica et Biophysica Acta, 1803, 3–19.Google Scholar
  22. Fluck, M. M., & Schaffhausen, B. S. (2009). Lessons in signaling and tumorigenesis from polyomavirus middle T antigen. Microbiology and Molecular Biology Reviews, 73, 542–563, Table of Contents.CrossRefPubMedGoogle Scholar
  23. Gomis-Ruth, F. X. (2009). Catalytic domain architecture of metzincin metalloproteases. The Journal of Biological Chemistry, 284, 15353–15357.CrossRefPubMedGoogle Scholar
  24. Jensen, L. D., Cao, R., & Cao, Y. (2009). In vivo angiogenesis and lymphangiogenesis models. Current Molecular Medicine, 9, 982–991.CrossRefPubMedGoogle Scholar
  25. Jost, M., Folgueras, A. R., Frerart, F., Pendas, A. M., Blacher, S., Houard, X., et al. (2006). Earlier onset of tumoral anglogenesis in matrix metalloproteinase-19-deficient mice. Cancer Research, 66, 5234–5241.CrossRefPubMedGoogle Scholar
  26. Jost, M., Vosseler, S., Blacher, S., Fusenig, N. E., Mueller, M. M., & Noel, A. (2008). Chapter 17: The surface transplantation model to study the tumor-host interface. In D. R. Edwards, G. Hoyer-Hansen, F. Blasi, & B. F. Sloane (Eds.), The cancer degradome: proteases and cancer biology, Springer, NY: (pp. 327–342).Google Scholar
  27. Lederle, W., Hartenstein, B., Meides, A., Kunzelmann, H., Werb, Z., Angel, P., et al. (2009). MMP13 as a stromal mediator in controlling persistent angiogenesis in skin carcinoma. Carcinogenesis, 31, 1175–1184.Google Scholar
  28. Lin, E. Y., Jones, J. G., Li, P., Zhu, L., Whitney, K. D., Muller, W. J., et al. (2003). Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. The American Journal of Pathology, 163, 2113–2126.CrossRefPubMedGoogle Scholar
  29. London, C. A., Sekhon, H. S., Arora, V., Stein, D. A., Iversen, P. L., & Devi, G. R. (2003). A novel antisense inhibitor of MMP-9 attenuates angiogenesis, human prostate cancer cell invasion and tumorigenicity. Cancer Gene Therapy, 10, 823–832.CrossRefPubMedGoogle Scholar
  30. Lopez-Otin, C., & Matrisian, L. M. (2007). Emerging roles of proteases in tumour suppression. Nature Reviews Cancer, 7, 800–808.CrossRefPubMedGoogle Scholar
  31. Lopez-Otin, C., & Overall, C. M. (2002). Protease degradomics: A new challenge for proteomics. Nature Reviews Molecular Cell Biology, 3, 509–519.CrossRefPubMedGoogle Scholar
  32. Maquoi, E., Sounni, N. E., Devy, L., Olivier, F., Frankenne, F., Krell, H. W., et al. (2004). Anti-invasive, antitumoral, and antiangiogenic efficacy of a pyrimidine-2,4,6-trione derivative, an orally active and selective matrix metalloproteinases inhibitor. Clinical Cancer Research, 10, 4038–4047.CrossRefPubMedGoogle Scholar
  33. Martin, M. D., Carter, K. J., Jean-Philippe, S. R., Chang, M., Mobashery, S., Thiolloy, S., et al. (2008). Effect of ablation or inhibition of stromal matrix metalloproteinase-9 on lung metastasis in a breast cancer model is dependent on genetic background. Cancer Research, 68, 6251–6259.CrossRefPubMedGoogle Scholar
  34. Martin, M. D., & Matrisian, L. M. (2007). The other side of MMPs: Protective roles in tumor progression. Cancer and Metastasis Reviews, 26, 717–724.CrossRefPubMedGoogle Scholar
  35. Masson, V., de la Ballina, L. R., Munaut, C., Wielockx, B., Jost, M., Maillard, C., et al. (2005). Contribution of host MMP-2 and MMP-9 to promote tumor vascularization and invasion of malignant keratinocytes. The FASEB Journal, 19, 234–236.PubMedGoogle Scholar
  36. Mott, J. D., & Werb, Z. (2004). Regulation of matrix biology by matrix metalloproteinases. Current Opinion in Cell Biology, 16, 558–564.CrossRefPubMedGoogle Scholar
  37. Mueller, M. M., & Fusenig, N. E. (2004). Friends or foes – bipolar effects of the tumour stroma in cancer. Nature Reviews Cancer, 4, 839–849.CrossRefPubMedGoogle Scholar
  38. Nicosia, R. (2009). The aortic ring model of angiogenesis: A quarter century of search and discovery. Journal of Cellular and Molecular Medicine, 13, 4113–4136.Google Scholar
  39. Nielsen, B. S., Egeblad, M., Rank, F., Askautrud, H. A., Pennington, C. J., Pedersen, T. X., et al. (2008). Matrix metalloproteinase 13 is induced in fibroblasts in polyomavirus middle T antigen-driven mammary carcinoma without influencing tumor progression. PLoS One, 3, e2959.CrossRefPubMedGoogle Scholar
  40. Noel, A., Jost, M., & Maquoi, E. (2008). Matrix metalloproteinases at cancer tumor-host interface. Seminars in Cell and Developmental Biology, 19, 52–60.CrossRefPubMedGoogle Scholar
  41. Nozawa, H., Chiu, C., & Hanahan, D. (2006). Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proceedings of the National Academy of Sciences of the United States of America, 103, 12493–12498.CrossRefPubMedGoogle Scholar
  42. Olson, E. S., Aguilera, T. A., Jiang, T., Ellies, L. G., Nguyen, Q. T., Wong, E. H., et al. (2009). In vivo characterization of activatable cell penetrating peptides for targeting protease activity in cancer. Integrative biology(Cambridge), 1, 382–393.CrossRefGoogle Scholar
  43. Otrock, Z. K., Hatoum, H. A., Awada, A. H., Ishak, R. S., & Shamseddine, A. I. (2009). Hypoxia-inducible factor in cancer angiogenesis: Structure, regulation and clinical perspectives. Critical Reviews in Oncology/Hematology, 70, 93–102.CrossRefPubMedGoogle Scholar
  44. Overall, C. M. (2004). Dilating the degradome: Matrix metalloproteinase 2 (MMP-2) cuts to the heart of the matter. Biochemical Journal, 383, 413–418.CrossRefGoogle Scholar
  45. Page-McCaw, A., Ewald, A. J., & Werb, Z. (2007). Matrix metalloproteinases and the regulation of tissue remodelling. Nature Reviews Molecular Cell Biology, 8, 221–233.CrossRefPubMedGoogle Scholar
  46. Parangi, S., O’Reilly, M., Christofori, G., Holmgren, L., Grosfeld, J., Folkman, J., et al. (1996). Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proceedings of the National Academy of Sciences of the United States of America, 93, 2002–2007.CrossRefPubMedGoogle Scholar
  47. Rhee, J. S., Diaz, R., Korets, L., Hodgson, J. G., & Coussens, L. M. (2004). TIMP-1 alters susceptibility to carcinogenesis. Cancer Research, 64, 952–961.CrossRefPubMedGoogle Scholar
  48. Ribatti, D., Nico, B., Crivellato, E., Roccaro, A. M., & Vacca, A. (2007). The history of the angiogenic switch concept. Leukemia, 21, 44–52.CrossRefPubMedGoogle Scholar
  49. Roy, R., Yang, J., & Moses, M. A. (2009). Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. Journal of Clinical Oncology, 27, 5287–5297.CrossRefPubMedGoogle Scholar
  50. Skobe, M., Rockwell, P., Goldstein, N., Vosseler, S., & Fusenig, N. E. (1997). Halting angiogenesis suppresses carcinoma cell invasion. Nature Medicine, 3, 1222–1227.CrossRefPubMedGoogle Scholar
  51. Sounni, N. E., Roghi, C., Chabottaux, V., Janssen, M., Munaut, C., Maquoi, E., et al. (2004). Up-regulation of vascular endothelial growth factor-A by active membrane-type 1 matrix metalloproteinase through activation of Src-tyrosine kinases. Journal of Biological Chemistry, 279, 13564–13574.CrossRefPubMedGoogle Scholar
  52. Szabova, L., Chrysovergis, K., Yamada, S. S., & Holmbeck, K. (2008). MT1-MMP is required for efficient tumor dissemination in experimental metastatic disease. Oncogene, 27, 3274–3281.CrossRefPubMedGoogle Scholar
  53. Tlsty, T. D. (2001). Stromal cells can contribute oncogenic signals. Seminars in Cancer Biology, 11, 97–104.CrossRefPubMedGoogle Scholar
  54. Tlsty, T. D., & Coussens, L. M. (2006). Tumor stroma and regulation of cancer development. Annual Review of Pathology, 1, 119–150.CrossRefPubMedGoogle Scholar
  55. Wojtowicz-Praga, S. (1999). Clinical potential of matrix metalloprotease inhibitors. Drugs in R&D, 1, 117–129.CrossRefGoogle Scholar
  56. Yana, I., Sagara, H., Takaki, S., Takatsu, K., Nakamura, K., Nakao, K., et al. (2007). Crosstalk between neovessels and mural cells directs the site-specific expression of MT1-MMP to endothelial tip cells. Journal of Cell Science, 120, 1607–1614.CrossRefPubMedGoogle Scholar
  57. Zhu, W. H., Guo, X., Villaschi, S., & Francesco Nicosia, R. (2000). Regulation of vascular growth and regression by matrix metalloproteinases in the rat aorta model of angiogenesis. Laboratory Investigation, 80, 545–555.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2011

Authors and Affiliations

  • Anne Masset
    • 1
  • Mehdi El Hour
    • 1
  • Sarah Berndt
    • 1
  • Nor Eddine Sounni
    • 1
  • Agnès Noel
    • 1
  1. 1.Groupe Interdisciplinaire de Génoprotéomique Appliquée-Cancer (GIGA-Cancer), Laboratory of Tumor and Developmental BiologyUniversity of LiegeLiègeBelgium

Personalised recommendations